| Characteristics of Treatment Responders to Galantamine | Characteristics of Treatment Responders to Galantamine Administration in the Patients With Alzheimer's Disease | NCT01029132 |
| Galantamine Effects on Nicotine Responses in Smokers | Galantamine Effects on Nicotine Responses in Smokers | NCT01417429 |
| Galantamine for Cognition in People With Schizophrenia | Effect of Nicotine Agonist Galantamine Added to High Potency Medications for Cognitive Function in Patients With Schizophrenia and Schizoaffective Disorder | NCT00320736 |
| Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease | A European Multi-Center Study to Determine the Safety and Efficacy of Galanthamine Hydrobromide 40mg/Day (32 mg /Day GAL Base, Tid Dose Regimen) in Patients Diagnosed With Alzheimer-Type Dementia | NCT00338117 |
| Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions | Randomized, 2-Way Crossover, Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions | NCT01190761 |
| Study to investigate the association between the response to a cholinergic challenge with galantamine and the clinical response to subsequent treatment with galantamine in patients with mild to moderate Alzheimer's Disease | Study to investigate the association between the response to a cholinergic challenge with galantamine and the clinical response to subsequent treatment with galantamine in patients with mild to moderate Alzheimer's Disease - A cholinergic challenge preceding galantamine treatment in patients with AD | NL-OMON38134 |
| An open-label study of two single oral doses of galantamine, examining the pharmacokinetics, safety, and tolerability in children with Down syndrome - N.A. | An open-label study of two single oral doses of galantamine, examining the pharmacokinetics, safety, and tolerability in children with Down syndrome - N.A. | EUCTR2006-003359-19-NL |
| Galantamine Treatment for Nonfluent Aphasia in Stroke Patients | Galantamine Treatment for Nonfluent Aphasia in Stroke Patients | NCT01129479 |
| A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia | An Open Pilot Study to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Pick's Disease/Frontotemporal Dementia /Pick Complex | NCT00416169 |
| The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease | The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease | NCT01054976 |
| Galantamine for Cognitive Deficits in Schizophrenia | Galantamine for Cognitive Deficits in Schizophrenia | NCT00463879 |
| A Phase II Randomized, Double-Blind, Double-Dummy, Parallel Group, Placebo Controlled Study of Galantamine + Sertraline, Galantamine or Sertraline in Obese Subjects | A Phase II Randomized, Double-Blind, Double-Dummy, Parallel Group, Placebo Controlled Study of Galantamine + Sertraline, Galantamine or Sertraline in Obese Subjects | EUCTR2007-000762-20-SE |
| Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia | Interventions to Test the Alpha7 Nicotinic Receptor Model in Schizophrenia | NCT00509067 |
| A double-blind, placebo-controlled, 2-year study of galantamine used to treat patients with Mild to Moderate Alzheimer's disease. | A Randomized, Double-blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-severe Alzheimer’s Disease | EUCTR2007-002780-27-DE |
| Galantamine Effects on Cognitive Function in Abstinent Cocaine Users | Galantamine Effects on Cognitive Function in Abstinent Cocaine Users | NCT00606801 |
| A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease | A Randomized, Double Blind, Active Control, Flexible Dose, Multicenter Study to Evaluate Galantamine HBr in the Treatment of Alzheimer's Disease:Safety and Effectiveness of an Immediate-release Table Formulation. | NCT00645190 |
| A Single Dose, Cross-over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers | A Bioequivalent Study to Compare Galantamine Oral Solution With Marketed Galantamine Capsule After Single Oral Administration of 10 mg. | NCT00645554 |
| A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease | A Randomized, Double-Blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease | NCT00679627 |
| Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder | The Efficacy and Safety of Galantamine for Dysfunction in Bipolar Disorder | NCT00741598 |
| Alzheimer and Sleep | Effects of Galantamine and Donépézil on the Amount and the Quality oh the Sleep in Patients Suffering From Alzheimer Disease. | NCT00750529 |
| Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations. | Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations. | EUCTR2008-006278-13-NL |
| Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse | Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse With Methadone Maintained Individuals | NCT00809835 |
| An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease | Placebo-controlled Confirmatory Study of Galantamine (R113675) for Alzheimer's Type Dementia | NCT00814801 |
| The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life | The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life | NCT00814658 |
| Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia | Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia | NCT01012167 |
| Effects of Galantamine on Cognition | Effects of Galantamine on Cognition | NCT01100775 |
| Galantamine Effects on Cognitive Function in Marijuana Users | Galantamine Effects on Cognitive Function in Marijuana Users | NCT00969696 |
| Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine | Non-interventional Study on Long-term Application of Galantamine and Nootropics in Patients With Alzheimer's Disease | NCT01009476 |
| Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER) | A Study of the Effect of Concomitant Administration of Multiple Doses of BMS-708163 on the Pharmacokinetics of Galantamine in Healthy Subjects | NCT01039194 |
| Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions | Randomized, 2-Way Crossover, Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions | NCT01190748 |
| Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke | Donepezil/ Galantamine in the Treatment of Post-stroke Cognitively Impaired Rehabilitating Elderly | NCT00227994 |
| Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease | Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8) | NCT00304629 |
| A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease | Long Term Treatment With Galantamine In Dementia | NCT00216502 |
| A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder | A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder | NCT00181675 |
| Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder | | NCT00181636 |
| A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder | A Phase 4 Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder | NCT00195845 |
| Treatment of Tardive Dyskinesia With Galantamine | Treatment of Tardive Dyskinesia With Galantamine | NCT00164242 |
| Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia | Adjunctive Galantamine for Treatment of Cognitive Impairments in Patients With Schizophrenia | NCT00176423 |
| An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms | An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms | NCT00161044 |
| The Video Imaging Synthesis of Treating Alzheimer's disease study | Evaluating the effects of galantamine HBr using Goal Attainment Scaling (GAS) in a placebo-controlled trial of mild to moderate Alzheimer's disease subjects | ISRCTN26167328 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF A COMBINATION OF GALANTAMINE (AN ACETYLCHOLINESTERASE INHIBITOR) PLUS TRIMIPRAMINE IN SMOKING CESSATION - Smoking Cessation Study | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF A COMBINATION OF GALANTAMINE (AN ACETYLCHOLINESTERASE INHIBITOR) PLUS TRIMIPRAMINE IN SMOKING CESSATION - Smoking Cessation Study | EUCTR2004-001174-25-IE |
| Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease | Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease | NCT00082602 |
| A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia. | A Study of Galantamine HBr as an Adjunctive Treatment to Atypical Antipsychotic Medications in Outpatients With Schizophrenia and Associated Cognitive Deficits. | NCT00077727 |
| A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia | A Randomized 26-Week, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia | NCT00035191 |
| A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease | A Double-blind, Randomized Pilot Study to Evaluate the Effects of Galantamine and Donepezil on Sleep and Attention and Gastrointestinal (GI) Tolerance in Patients With Mild to Moderate Alzheimer's Disease (AD) | NCT00035204 |
| Evaluation of Galantamine in the Treatment of Alzheimer's Disease | Placebo Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy Under a Slow-Titration Regimen | NCT00000172 |
| Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance | Evaluation of Three Potential CNS Pretreatments for Soman Exposure - Huperzine A, Donepezil, and Galantamine - on Human Performance | NCT01194336 |
| Galantamine Executive Function in Parkinson's Disease | Investigator Initiated Study: Galantamine CR Potential Enhancement of Attentional and Executive Function in Non-Demented Patients With Parkinson's Disease | NCT00211588 |
| Galantamine in the Treatment of Post-Traumatic Headache | Galantamine in the Preventive Treatment of Chronic Post-Traumatic Headache | NCT00219869 |
| Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study | Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study. | NCT00216593 |
| The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type | A Prospective, Open-labeled, Multicenter Study of Galantamine on the Attention and Frontal Function of the Patients With Dementia of Alzheimer Type | NCT00216515 |
| An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period | An Observational Study of Clinical Outcomes and Safety Profile of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period | NCT00299676 |
| A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease | Open Observational Study of Galantamine Hydrobromide Administration for the Treatment of Patients With Mild to Moderate Dementia of the Alzheimer Type | NCT00297362 |
| A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia | The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia | NCT00261573 |
| A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease | Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease | NCT00253201 |
| A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease | Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease | NCT00253188 |
| Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation | Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation | NCT00253214 |
| A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease | Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial | NCT00253227 |
| A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease. | Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: A Cardiac Safety Study. | NCT00309725 |
| Galantamine Versus Placebo in Childhood Autism | Galantamine Versus Placebo in Childhood Autism | NCT00252603 |
| A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment | A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease | NCT00236431 |
| A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment | A Randomized Double Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease. | NCT00236574 |
| Efficacy of Galantamine to Treat Schizophrenia | An Open-Label Trial of Adjunctive Galantamine Maintenance Therapy to Treat Functional Impairments in Chronic Outpatients With Schizophrenia | NCT00232349 |
| Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies | An Open Label 24-Week, Flexible Dose Trial to Assess the Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies | NCT00230997 |
| Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment | Evaluation de l'efficacité de la Galantamine Versus Placebo associée à Une Revalidation Neuropsychologique Chez Des Patients présentant un Trouble Cognitif après un Premier Infarctus cérébral : étude en Neuroimagerie Fonctionnelle | NCT01508494 |
| Safety Study of Galantamine in Tic Disorders | Pilot Examination of Galantamine in the Management of Tic Disorders | NCT00226824 |
| Galantamine Augmentation of Escitalopram for Treatment of Depression | Galantamine Augmentation of Escitalopram for Treatment of Depression Associated Cognitive Impairment in Outpatients - A Randomized Single Blind Clinical Trial | NCT00423969 |
| A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment | An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Galantamine HBr in the Treatment of Mild Cognitive Impairment | NCT00240695 |
| Cognitive REmediation After Trauma Exposure Trial = CREATE Trial | Randomized Controlled Trial of Galantamine, Methylphenidate, and Placebo for the Treatment of Cognitive Symptoms in Patients With Traumatic Brain Injury (TBI) and/or Posttraumatic Stress Disorder (PTSD) | NCT01416948 |
| An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease. | Placebo-Controlled, Double-Blind Study of Galantamine (R113675) in the Treatment of Alzheimer's Disease. | NCT00301574 |
| The ACER-study - examining the effects of galantamine on gait. | The ACER-study - the effects of galantamine on the variability and stability of walking among patients with Alzheimer's disease. - The ACER-study | EUCTR2011-006011-62-NL |
| Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil | Evaluation of Efficacy and Safety of Galantamine in Subjects With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil | NCT01478633 |
| Study of Galantamine for the treatment of Alzheimer's disease based on real world | Study of Galantamine for the treatment of Alzheimer's disease based on real world | ChiCTR2400094516 |
| A Single-dose, Randomized, Open-label, Crossover Bioequivalence Study of Generic Galantamine 8 mg Capsule and Reference Product in Healthy Thai Volunteers under Fasting and Fed Conditions | A Single-dose, Randomized, Open-label, Crossover Bioequivalence Study of Generic Galantamine 8 mg Capsule and Reference Product in Healthy Thai Volunteers under Fasting and Fed Conditions | TCTR20241215009 |
| Clinical registration study on the safety of Galantamine hydrobromide injection based on real world | Clinical registration study on the safety of Galantamine hydrobromide injection based on real world | ChiCTR2400082365 |
| A real-world study of the safety and efficacy of galanthamine hydrobromide in the treatment of cognitive impairment | A real-world study of the safety and efficacy of galanthamine hydrobromide in the treatment of cognitive impairment | ChiCTR2400081930 |
| A study to investigate the association between the acute response and long-term clinical response to galantamine in patients with mild to moderate Alzheimer’s Disease | Study to investigate the association between the response to a cholinergic challenge with galantamine and the clinical response to subsequent treatment with galantamine in patients with mild to moderate Alzheimer’s Disease | ISRCTN82825745 |
| The effects of galantamine on brain network topology in patients with Alzheimer's disease | The effects of galantamine administration on brain network topology in patients with Alzheimer's disease (AD): A possible new biomarker for pharmacotherapy of AD | JPRN-jRCTs031180337 |
| Evaluation the Effect of Adding Galantamine to Second Generation Antipsychotics | Evaluation the Effect of Adding Galantamine to Second Generation Antipsychotics, on Negative Symptoms of Schizophrenia | IRCT20181117041682N2 |
| Bioequivalence Study of 8 mg Galantamine HBr Prolonged Release Capsules under Fasting and Fed Conditions in Healthy Volunteers | Bioequivalence Study of 8 mg Galantamine HBr Prolonged Release Capsules under Fasting and Fed Conditions in Healthy Volunteers | TCTR20190227001 |
| Galantamine and CBT4CBT Pilot | Pilot Study of Galantamine and CBT4CBT to Reduce Post-taper Relapse for MAT | NCT03547622 |
| Effect of Galantamine on Inflammation and Cognition | Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction | NCT03384784 |
| Subarachnoid Hemorrhage Recovery And Galantamine | A Pilot Parallel Double-Blind, Randomized Trial of Galantamine for Subarachnoid Hemorrhage | NCT02872857 |
| Evaluation of cognitive, affective, olfactory functions and sleep disturbance improvement in Dementia with Lewy Bodies patients treated with Galantamine | Evaluation of cognitive, affective, olfactory functions and sleep disturbance improvement in Dementia with Lewy Bodies patients treated with Galantamine - Evaluation of cognitive, affective, olfactory function and sleep disturbance improvement in DLB patients treated with Galantamine | JPRN-UMIN000022860 |
| Evaluation Of the, Galantamine and Memantine co-administration on the Cognitive Deficits | Evaluation Of the, Galantamine and Memantine co-administration on the Cognitive Deficits induced by Eelctro Convalsive Therapy: A Randomized doubel blind Clinical Trial | IRCT2015051720913N1 |
| Effectiveness of Galantamine on the care burden of family caregivers of patients with Alzheimer's disease | Effectiveness of Galantamine on the care burden of family caregivers of patients with Alzheimer's disease - Effectiveness of Galantamine on the care burden in Alzheimer's disease | JPRN-UMIN000009934 |
| A double-blind, placebo-controlled study of the impact of prophylactic treatment with Galantamine 8mg of cognitive impairment during an electroconvulsive therapy (ECT) in patients with major depressive desorder (MDD). | A double-blind, placebo-controlled study of the impact of prophylactic treatment with Galantamine 8mg of cognitive impairment during an electroconvulsive therapy (ECT) in patients with major depressive disorder (MDD). | EUCTR2014-004393-41-BE |
| A randomized, double blind, placebo-controlled crossover study to investigate the effects of cholinergic and serotonergic challenges with galantamine and citalopram on resting state FMRI in aging and dementia. | A randomized, double blind, placebo-controlled crossover study to investigate the effects of cholinergic and serotonergic challenges with galantamine and citalopram on resting state FMRI in aging and dementia. - Pharmacological resting state FMRI in aging and dementia. | NL-OMON37710 |
| The effects of galantamine administration on brain network topology in patients with Alzheimer's disease (AD): A possible new biomarker for pharmacotherapy of AD | The effects of galantamine administration on brain network topology in patients with Alzheimer's disease (AD): A possible new biomarker for pharmacotherapy of AD - The effects of galantamine administration on brain network topology in patients with Alzheimer's disease | JPRN-UMIN000018749 |
| Effect of Galantamine on Smoking Abstinence | The Effect of the Acetylcholinesterase Inhibitor, Galantamine, on Short-term Abstinence | NCT01548638 |
| Galantamine in the treatment of autism | Galantamine added to risperidone in the treatment of Autism: A double blind and placebo controlled trial | IRCT201204081556N40 |
| A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease | An Observational, Multi-Center Study to Demonstrate That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease | NCT01734395 |
| The efficacy and response of switching from donepezil to galantamine in Alzheimer disease: multi-modal neuroimaging analysis (structural and functional neuroimaging) of open-label, clinical trial | The efficacy and response of switching from donepezil to galantamine in Alzheimer disease: multi-modal neuroimaging analysis (structural and functional neuroimaging) of open-label, clinical trial - Multi-modal neuroimaging analysis of open-trial of switching from donepezil to galantamine | JPRN-UMIN000009470 |
| Effect of Galantamine on Short-term Abstinence | Repurposing Cholinesterase Inhibitors for Smoking Cessation. | NCT01669538 |
| Effect of Galantamine on Short-term Abstinence | Repurposing Cholinesterase Inhibitors for Smoking Cessation | NCT01845961 |
| A randomized study comparing effects of donepezil and galantamine in Alzheimer disease :attentional function of clinical trial | A randomized study comparing effects of donepezil and galantamine in Alzheimer disease :attentional function of clinical trial - A randomized study comparing effects of donepezil and galantamine in Alzheimer disease | JPRN-UMIN000012544 |
| Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia | A Proof-of Concept Trial of Galantamine and Memantine for Cognitive Impairments in Schizophrenia: Is the Combination Effective? | NCT02234752 |
| Galantamine Effects in Patients With Metabolic Syndrome | Effects of Cholinergic Stimulation on Visceral Fat, Oxidative Stress and Inflammatory Markers in Patients With Metabolic Syndrome: a Randomized Clinical Trial | NCT02283242 |
| Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine | The Use of Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine | NCT02420327 |
| The efficacy and response of switching from either donepezil or galantamine to rivastigmine transdermal patch in Alzheimer disease: multi-modal neuroimaging analysis (structural and functional neuroimaging) of open-label, clinical trial | The efficacy and response of switching from either donepezil or galantamine to rivastigmine transdermal patch in Alzheimer disease: multi-modal neuroimaging analysis (structural and functional neuroimaging) of open-label, clinical trial - Multi-modal neuroimaging analysis of open-trial of switching from either donepezil or galantamine to rivastigmine | JPRN-UMIN000010556 |
